MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.445
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases

Scientific Reports
Multidisciplinary
2017English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

P002 Surgical Resection Improves the Survival of NSCLC Patients With Pleural Metastasis Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.15-30 Survival of Patients With Advanced NSCLC Treated With First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-24 Efficacy of EGFR-TKIs Compared With Chemotherapy as First-Line Therapy in Patients With EGFR Rare Mutation Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-23 EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy